trending Market Intelligence /marketintelligence/en/news-insights/trending/wSggQI-bRU9WcAiPktNzKQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Qiagen sells NeXtal Biotechnologies unit to Calibre Scientific

Los Angeles-based Calibre Scientific Inc. acquired Qiagen NV's NeXtal Biotechnologies unit, which specializes in producing protein crystallization plates and screens.

NeXtal's products are sold in the academic, biotechnology and pharmaceutical markets and are used to study the molecular structure of a protein, primarily for creating certain medicines including cancer treatments.

Calibre Scientific CEO Ben Travis said NeXtal's proprietary products complement its offerings.

Financial details of the transaction were not disclosed.

NeXtal Biotechnologies was acquired by Qiagen in 2005 for $14.2 million.